For example, blocking IL1B expression in IL1B+ macrophages could prevent the production of angiogenesis-promoting MC4 via the IL1B/ADRB2 pathway, resulting in the inhibition of tumor growth, a reduction in the TNF+/VEGFA+ ratio, and an increase in patient prognosis. Here, ADRB2 is linked to neoplasm.